Vtama(tapinarof)
Vtama 1 % Topical Cream
NO BOXED WARNING
Dosage & Administration
Dosage & Administration
drug label
Vtama Prescribing Information
Financial Assistance
Financial Assistance Programs
Vtama retails for $1,468 per dose without insurance or financial assistance.Depending on your patient's insurance situation and other eligibility criteria, they may be able to get Vtama for significantly less. Review the program information below to determine what program can offer your patient the most benefits.Copay Card Program$0 Copay
Available for
commercial
Forms
Foundation ProgramFirst dose for $0
Available for
medicare
uninsured
Eligibility requirements
- Uninsured
- Medicare
- Medicaid
- Household annual adjusted gross income <= 250% FPL.
Forms
patient education
Vtama Patient Education
Getting started on Vtama
To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link
Patient toolkit
people also ask
Vtama FAQs
1. Is VTAMA cream safe to use during pregnancy?The available data on VTAMA cream use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal reproduction studies, there were no significant adverse effects at certain doses in pregnant rats and rabbits. However, the estimated background risk of major birth defects and miscarriage for pregnant women using VTAMA cream is unknown.
2. What is the background risk of major birth defects and miscarriage during pregnancy?All pregnancies have a background risk of major birth defects, loss, and other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
3. What does the animal data reveal about VTAMA cream use during pregnancy?In animal studies, VTAMA cream did not result in significant adverse effects at certain doses in pregnant rats and rabbits, except for an increased incidence of skeletal variations in rabbits at a high dose. However, no embryofetal lethality or major fetal malformations were observed at recommended human doses.
4. Can tapinarof be detected in human milk when using VTAMA cream during lactation?No data are available regarding the presence of tapinarof in human milk when using VTAMA cream. However, tapinarof was detected in rat offspring, suggesting that it may be transferred into the milk of lactating rats. When a drug is present in animal milk, it is likely that it will be present in human milk, so the potential effects on breastfed infants should be considered.
5. Is VTAMA cream safe for pediatric use in psoriasis patients under 18 years of age?Safety and efficacy of VTAMA cream have not been established in pediatric subjects with psoriasis under 18 years of age. Therefore, its use in this age group is not recommended.
6. What are the findings from the juvenile animal toxicity study for VTAMA cream?In a juvenile animal toxicity study, VTAMA cream was administered to juvenile rats at various doses. Renal pelvic dilatation was observed at higher doses, but no adverse effects in juvenile animals were noted at lower doses.
7. Is VTAMA cream safe for use in elderly individuals?In clinical trials, there were no overall differences in efficacy, safety, or tolerability observed between elderly subjects (65 years of age and older) and younger adult subjects when using VTAMA cream.
FAQ Data Source